The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. (2002)

Peer-Reviewed Study · Ji-ichiro Sasaki; Rajagopal Ramesh; Sunil Chada et al. · November 2002

Ji-ichiro Sasaki et al., 2002-11: Lung cancer study in which oral mebendazole shrank subcutaneous xenografts and reduced experimental lung colonies in mice with less toxicity than paclitaxel.

Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.

Ji-ichiro Sasaki et al., 2002-11: Lung cancer study in which oral mebendazole shrank subcutaneous xenografts and reduced experimental lung colonies in mice with less toxicity than paclitaxel. Study type: human NSCLC cell lines plus mouse s.c. xenograft and experimental lung metastasis models. N: not stated in the abstract. Country: USA (MD Anderson Cancer Center, Houston). Dose: not stated in the abstract text captured; route oral; schedule and duration not stated in the abstract. Funder: US NIH CA16672, P-50-CA70907, P01 CA78778-01A1. Declared conflicts: no COI statement in the record. Comparator: paclitaxel-treated mice for toxicity, and untreated tumour-bearing mice. Same article as the C2 row (Sasaki et al. 2002); it is recorded twice because it carries two separate claims. Also filed as MBB-12 (claims C2, C6). Study type: animal.